Galzin Now Available for Maintenance Treatment of Wilson Disease

Galzin^® (zinc acetate capsules) is now available for maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent, according to Eton Pharmaceuticals.

Wilson disease is an autosomal recessive metabolic defect in hepatic excretion of copper in the bile, resulting in accumulation of excess copper in the liver, and subsequently in other organs (eg, brain, kidneys, eyes, bone, muscles). Galzin capsules contain zinc, which blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper. 

Galzin was approved by the Food and Drug Administration based on studies utilizing various zinc acetate regimens to assess outcomes in patients with Wilson disease. Results from these studies showed treatment with zinc acetate led to adequate copper balance in most patients and no deterioration of clinical parameters such as neuropsychiatric status and liver function tests.

Galzin is supplied as capsules containing 25mg and 50mg of zinc. Maintenance treatment with Galzin can be considered once a patient is no longer symptomatic following initial therapy with chelating agents. Monitoring is required to assure the adequacy of zinc acetate therapy.

Galzin is available exclusively through Optime Care, a specialty pharmacy. A patient referral form for clinicians is available here. Additionally, the product can be e-prescribed by selecting Optime Care as the pharmacy.

Commenting on the availability of Galzin, Sean Brynjelsen, CEO of Eton Pharmaceuticals said, “Due to historic availability and affordability challenges, many patients have turned to unapproved compounded products or over-the-counter supplements to manage their Wilson disease. We are dedicated to increasing both access to and awareness of this critical medication.”

This article originally appeared on MPR